Boston Scientific Corporation
BSXLast close · Oct 16, 202644.39+0.25 (+0.57%)
Market cap$64.3B
Of the 85 managers this site tracks, 6 held Boston Scientific (BSX) at the end of Q2 2026, their latest 13Fs. The largest position by value was Lee Ainslie's, $253.4M; Sarah Ketterer's ($30.7M) and Bridgewater's ($18.9M) follow. No Schedule 13D or 13G is on file for BSX from the activists and large holders the site follows.
Superinvestors holding BSX
| Manager | Firm | Quarter | Shares | Value |
|---|---|---|---|---|
| Lee Ainslie | Maverick Capital Ltd | Q2 2026 | 6M | $253.4M |
| Sarah Ketterer | Causeway Capital Management LLC | Q2 2026 | 720,339 | $30.7M |
| Bridgewater | Bridgewater Associates, LP | Q2 2026 | 442,036 | $18.9M |
| Dodge & Cox | Dodge & Cox | Q2 2026 | 87,485 | $3.7M |
| Mairs & Power | Mairs & Power Inc | Q2 2026 | 9,914 | $423,130 |
| Polen Capital | Polen Capital Management LLC | Q2 2026 | 4,750 | $202,733 |
13D/13G are SEC beneficial-ownership disclosures, triggered only above 5%; a 13F is a quarterly snapshot filed up to 45 days after quarter end. Superinvestor names link to their full portfolios under Investors.